Durgical
EN
Open the app

A high platelet count: reactive or essential thrombocythaemia?

  • Diagnostic approach

Most high platelet counts are a sign of something else: iron deficiency, infection, inflammation or cancer. Find that first; only a few are marrow disease.

Updated

What it is

Thrombocytosis is a platelet count above about 450 × 10⁹/L. Most cases are reactive (secondary): cytokines such as interleukin-6 raise thrombopoietin and the normal marrow makes more platelets. A minority are clonal, a myeloproliferative neoplasm such as essential thrombocythaemia (ET), polycythaemia vera, primary myelofibrosis or chronic myeloid leukaemia, or a myelodysplastic syndrome, in which the marrow makes platelets without the signal.

Red flags

  • Red flags for a clonal cause: count persistently high with no cause found, a big spleen, clots or bleeding, high haemoglobin or white cells too, abnormal cells on the smear.
  • Reactive causes: iron deficiency (the commonest), infection, inflammatory disease, cancer, recent surgery, trauma or bleeding, and absent or non-working spleen.
  • Rebound thrombocytosis follows recovery from alcohol excess, chemotherapy, or treatment of B12 deficiency or ITP.
  • ET drivers: JAK2 in about half, CALR in about a quarter, MPL in a few; about one in ten is 'triple-negative'.
  • Every unexplained thrombocytosis needs BCR::ABL1 testing: CML can present with platelets alone.
  • At very high counts (around 1,000 × 10⁹/L or more) platelets strip large von Willebrand factor multimers from the blood, so patients bleed rather than clot (acquired von Willebrand syndrome).

The decision tree, step by step

  1. Confirm the count is real: look at the smear for platelet clumps, red cell fragments or tiny spherocytes that machines count as platelets.
  2. Look for the fire: history of bleeding, infection, inflammation, surgery, cancer or splenectomy; check ferritin and CRP.
  3. Treat what you find and repeat the count: reactive thrombocytosis settles as the cause resolves.
  4. Persistent and unexplained, or with red flags: test JAK2, then CALR and MPL if negative, and BCR::ABL1 in all.
  5. Refer for a marrow biopsy: it separates ET from early myelofibrosis and confirms the diagnosis when no mutation is found.
  6. If ET is confirmed, grade the clot risk by age, previous thrombosis and JAK2 status, and treat by that risk.

Smoke from a fire, or a faulty alarm?

FeatureReactive thrombocytosisEssential thrombocythaemia
Cause in sightYes: iron deficiency, infection, inflammation, cancer, no spleenNone
CourseFalls when the cause is treatedPersists for months
CRP and ferritinCRP often high; ferritin low in iron deficiencyUsually normal
SpleenNormal (or absent after splenectomy)Sometimes mildly enlarged
Clots and bleedingRisk comes mostly from the underlying illnessArterial and venous clots; bleeding at very high counts
Decisive testThe count normalisesJAK2, CALR or MPL; marrow with large, mature megakaryocytes

In clinical practice

  • A woman with heavy periods and a platelet count of 700 × 10⁹/L most likely has iron deficiency: treat the iron and recheck.
  • ET often presents in middle or older age (and in some younger women) with headache, visual disturbance, burning red fingers and toes, or a stroke or clot; many are found by chance.
  • After splenectomy or with a non-working spleen (sickle cell disease), platelets stay high for long periods: this is expected and not ET.
  • ET treatment is by risk: low-dose aspirin for most; cytoreduction (hydroxycarbamide, anagrelide or interferon, the last preferred in pregnancy) for those over 60 or with a previous clot.
  • Before giving aspirin to a patient with a very high count, check von Willebrand factor activity: aspirin can turn mild bleeding into serious bleeding.

Tests and next step

  • First line: repeat count with smear, ferritin and iron studies, CRP, kidney and liver tests.
  • Persistent, unexplained: JAK2 V617F, then CALR and MPL; BCR::ABL1 in every case.
  • Platelets very high or the patient bleeds: von Willebrand factor activity and antigen before antiplatelet drugs.
  • A high potassium in a sample from a patient with very high platelets may be false (released from platelets as the blood clots in the tube): repeat on a plasma sample.
  • Marrow biopsy, with cytogenetics, when the mutations are negative or myelofibrosis is suspected.

Common traps

  • Diagnosing ET before correcting iron deficiency: it is the commonest cause of a high platelet count, and iron deficiency can also mask PV.
  • Forgetting BCR::ABL1: CML can look like ET, and its treatment is completely different.
  • Starting aspirin at very high platelet counts: check first for acquired von Willebrand syndrome.
  • Treating a high potassium in a clotted sample with a high platelet count: it is only an artefact.
  • Assuming that a reactive thrombocytosis itself causes clots: the clot risk comes from the underlying disease, so the count is not usually lowered.

Test yourself

Think of the answer, then tap the question to see it.

Why must BCR::ABL1 be tested in every patient with unexplained persistent thrombocytosis?

CML can present with a high platelet count alone and look like ET; it needs a tyrosine kinase inhibitor, not ET treatment.

A patient with a platelet count far above 1,000 × 10⁹/L has nosebleeds. Why can aspirin be dangerous here?

Very high platelet counts remove large von Willebrand factor multimers (acquired von Willebrand syndrome); aspirin adds a platelet defect and bleeding worsens.

What is the first test to order in a young woman with heavy periods and a high platelet count?

Ferritin: iron deficiency is the commonest cause of thrombocytosis, and the count falls once the iron is replaced.

Why does a high potassium in a patient with very high platelets not always need treatment?

Platelets release potassium as the sample clots in the tube (pseudohyperkalaemia); a plasma sample shows the true value.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Essential thrombocythemia (MedlinePlus (U.S. National Library of Medicine), 2025); Essential thrombocythemia: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026); Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.